In breast cancer cells, the use of an MEK inhibitor (trametinib) in combination with rosiglitazone for adipogenic transdifferentiation therapy strongly promoted the direct lineage differentiation of these cancer cells. The gene discussed is MAP2K7; the disease is cancer.